Cargando…

A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma

Background. Currently, bevacizumab (BEV), an antiangiogenic agent, is used as an adjunctive therapy to re-irradiation and surgery in patients with recurrent high-grade gliomas (rHGG). BEV has shown to decrease enhancement on MRI, but it is often unclear if these changes are due to tumor response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Kendall L, O’Neal, Christen M, Andrews, Bethany J, Westrup, Alison M, Battiste, James D, Glenn, Chad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369430/ https://www.ncbi.nlm.nih.gov/pubmed/34409294 http://dx.doi.org/10.1093/noajnl/vdab003

Ejemplares similares

A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma
por: Prather, Kiana Y, et al.
Publicado: (2022)

Management of nonoperative cervical spine fractures: An institutional analysis of follow-up duration and image acquisition
por: Westrup, Alison M., et al.
Publicado: (2022)

Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature
por: Palejwala, Ali H, et al.
Publicado: (2022)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
por: Smits, Anja, et al.
Publicado: (2011)

Change in (18)F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment
por: Yamaguchi, Shigeru, et al.
Publicado: (2016)

The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI
por: Santo, Giulia, et al.
Publicado: (2022)

COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2019)

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
por: Bovi, Joseph A., et al.
Publicado: (2020)

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
por: Cohen, Adam L., et al.
Publicado: (2020)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Utility of FET-PET in detecting high-grade gliomas presenting with equivocal MR imaging features
por: Puranik, Ameya D., et al.
Publicado: (2019)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma
por: Chan, Joseph, et al.
Publicado: (2020)

Amino acid tracers in PET imaging of diffuse low-grade gliomas: a systematic review of preoperative applications
por: Näslund, Olivia, et al.
Publicado: (2018)

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
por: Kulinich, Daniel P., et al.
Publicado: (2021)

OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera
por: Towner, Rheal A., et al.
Publicado: (2022)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
por: Kassubek, Rebecca, et al.
Publicado: (2023)

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis
por: Cho, Se Jin, et al.
Publicado: (2020)

(11)C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence
por: Bag, Asim K., et al.
Publicado: (2022)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

RT-05 THE RESULTS OF GAMMA KNIFE RADIOSURGERY WITH BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GRADE II/III GLIOMAS
por: Asanome, Taku, et al.
Publicado: (2019)

Additive Value of Dynamic FDOPA PET/CT for Glioma Grading
por: Girard, Antoine, et al.
Publicado: (2021)

A Systematic Review of Amino Acid PET Imaging in Adult-Type High-Grade Glioma Surgery: A Neurosurgeon’s Perspective
por: De Marco, Raffaele, et al.
Publicado: (2022)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
por: Castelli, Barbara, et al.
Publicado: (2023)

Navigated transcranial magnetic stimulation following awake craniotomy for resection of glioma: Description of two cases
por: O’Neal, Christen M., et al.
Publicado: (2020)

A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review
por: Muthukumar, Sankar, et al.
Publicado: (2022)

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017)

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
por: Rahmathulla, Gazanfar, et al.
Publicado: (2013)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
por: Kim, Ju-Hwi, et al.
Publicado: (2017)

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma
por: Martínez-González, Alicia, et al.
Publicado: (2020)

The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients
por: Waltenberger, Maria, et al.
Publicado: (2022)

LGG-29. Use of Bevacizumab in Pediatric Low-grade Glioma: Ten-year experience in a single center
por: Rafael, Margarida Simão, et al.
Publicado: (2022)

Utility of Nuclear Morphometry in Predicting Grades of Diffusely Infiltrating Gliomas
por: Boruah, Dibyajyoti, et al.
Publicado: (2013)

Clinical utility of arterial spin labeling for preoperative grading of glioma
por: Fu, Jun, et al.
Publicado: (2018)

Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
por: Salas, Lucas A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7kvqeoejnt9hsk9u92lv2ua26l